Oculis Advances Privosegtor in Optic Neuritis Trial with First Patient Dosed
Event summary
- First patient treated in PIONEER-1 registrational trial for Privosegtor in optic neuritis (ON).
- Trial follows positive Phase 2 ACUITY data and FDA Breakthrough Therapy, EMA PRIME designations.
- Primary endpoint: Proportion of patients achieving at least a 15-letter gain in vision at Month 3.
- FDA agreed to Special Protocol Assessment (SPA) for trial design, supporting potential NDA submission.
- IND submission for acute MS relapses planned for Q4 2026.
The big picture
Oculis is advancing Privosegtor as a potential first-in-class neuroprotective therapy for optic neuritis, a condition with no approved treatments. The PIONEER-1 trial represents a critical step in validating the drug’s efficacy, supported by strong regulatory designations and positive Phase 2 results. Success could position Privosegtor as a foundational therapy for neuro-ophthalmic and neurological diseases, expanding Oculis’ pipeline beyond ON into broader neuroprotection applications.
What we're watching
- Clinical Execution
- Whether Oculis can maintain rapid enrollment and operational efficiency across multidisciplinary centers.
- Regulatory Pathway
- The pace at which PIONEER-1 data could support an NDA submission and potential approval for Privosegtor.
- Pipeline Expansion
- How successful Phase 2 data in ON could accelerate Privosegtor’s development for acute MS relapses.